Results 61 to 66 of 66 matches
Category 5 - DIAGNOSTIC IMAGING SERVICES
58909 - Additional Information
Barium or other opaque meal of one or more of pharynx, oesophagus, stomach or duodenum, with or without preliminary plain films of pharynx, chest or duodenum, not being a service associated with a service to which item 57939, 57942 or 57945 applies (R)
Fee: $97.40 Benefit: 75% = $73.05 85% = $82.80
(See para IN.0.19 of explanatory notes to this Category)
Category 5 - DIAGNOSTIC IMAGING SERVICES
58912 - Additional Information
Barium or other opaque meal of oesophagus, stomach, duodenum and follow through to colon, with or without screening of chest and with or without preliminary plain film (R)
Fee: $119.45 Benefit: 75% = $89.60 85% = $101.55
(See para IN.0.19 of explanatory notes to this Category)
Category 5 - DIAGNOSTIC IMAGING SERVICES
61373 - Additional Information
Gastro-oesophageal reflux study, including delayed imaging on a separate occasion when performed (R)
Fee: $489.70 Benefit: 75% = $367.30 85% = $416.25
(See para IN.0.19 of explanatory notes to this Category)
Category 5 - DIAGNOSTIC IMAGING SERVICES
61376 - Additional Information
Oesophageal clearance study (R)
Fee: $143.35 Benefit: 75% = $107.55 85% = $121.85
(See para IN.0.19 of explanatory notes to this Category)
Category 5 - DIAGNOSTIC IMAGING SERVICES
61577 - Additional Information
Whole body FDG PET study, performed for the staging of proven oesophageal or GEJ carcinoma, in patients considered suitable for active therapy (R).
Fee: $953.00 Benefit: 75% = $714.75 85% = $854.30
Category 6 - PATHOLOGY SERVICES
73342 - Additional Information
An in situ hybridisation (ISH) test of tumour tissue from a patient with metastatic adenocarcinoma of the stomach or gastro-oesophageal junction, with documented evidence of human epidermal growth factor receptor 2 (HER2) overexpression by immunohistochemical (IHC) examination giving a staining intensity score of 2+ or 3+ on the same tumour tissue sample, requested by, or on the advice of, a specialist or consultant physician who manages the treatment of the patient to determine if the requirements relating to HER2 gene amplification for access to trastuzumab under the Pharmaceutical Benefits Scheme are fulfilled.
Fee: $315.40 Benefit: 75% = $236.55 85% = $268.10
(See para PN.1.2 of explanatory notes to this Category)
Results 61 to 66 of 66 matches
Legend
- Assist - Addition/Deletion of (Assist.)
- Amend - Amended Description
- Anaes - Anaesthetic Values Amended
- Emsn - EMSN Change
- Fee - Fee Amended
- Renum - Item Number Change (renumbered)
- New - New Item
- NewMin - New Item (previous Ministerial Determination)
- Qfe - QFE Change